![[18F-FDG] PET/CT Role in Lymphoma](/kep/978/303/225/633/1.jpg "[18F-FDG] PET/CT Role in Lymphoma")
[18F-FDG] PET/CT Role in Lymphoma
- Publisher's listprice EUR 149.79
-
58 507 Ft (55 721 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 11 701 Ft off)
- Discounted price 46 806 Ft (44 577 Ft + 5% VAT)
- Discount is valid until: 30 June 2026
Subcribe now and take benefit of a favourable price.
Subscribe
51 486 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Springer Nature Switzerland
- Date of Publication 2 July 2026
- ISBN 9783032256331
- Binding Hardback
- No. of pages249 pages
- Size 254x178 mm
- Language English
- Illustrations II, 249 p. 34 illus., 29 illus. in color. 700
Categories
Long description:
In this book, the potential benefits and limitations of advanced PET/CT techniques and technologies that support novel chemotherapy and radiotherapy approaches in the treatment of lymphoma are described. Particular attention is paid to the major challenge of incorporating progress in quantitative imaging technology, like new imaging variables like Dmax, MTV, TLG, etc.
In the volume, the main evidence about the role of PET/CT in lymphoma, dividing for variants are summarised. The role of 18F-FDG PET/CT in lymphoma is well demonstrated especially in FDG-avid lymphoma (DLBCL, HL, FL), but new findings are emerging about other variants, such as MCL, MALT, Burkitt, etc. Moreover, the technological advancement (new tomographs, new radiotracers, new software) may have a crucial role in the future.
A detailed description of the causes of false-positive, false-negative, and common pitfalls in interpreting the images and the patient preparation for 18F-FDG PET/CT in this setting is given by Authors.
The book, written by international experts about PET/CT role in lymphoma, represents a clear and evidence-based book of interest for all physician dealing with Nuclear Medicine and Hematology/Oncology.
MoreTable of Contents:
"
Part I. Introduction.- Lymphoma classification.- PET/CT principles.- PET/CT “quantitative” biomarkers in lymphoma.- Part II. [18F]FDG PET/CT in Hodgkin Lymphoma.- Hodgkin Lymphoma.- Part III. [18F]FDG PET/CT in non-Hodgkin Lymphoma.- Diffuse large B Cell Lymphoma (DLBCL).- Follicular Lymphoma (FL).- Mantle Cell Lymphoma.- T Cell Lymphoma.- Marginal Zone Lymphoma.- Burkitt Lympoma (BL).- Part IV. [18F-FDG] PET/CT Specific Populations.- Pediatric Population.- An update on [18F-FDG] PET/CT for diagnosing, staging, and guiding therapy in HIV-associated lymphoma.- Lymphoma and [18F]FDG PET/CT in Elderly.- Part V. Future Perspectives.- New scanners.- Novel radiopharmaceuticals for lymphoma.- Radiomics And Artificial Intelligence.
" More
